30 Day Trial

Anika Therapeutics 4Q16 and 2016 Revenue

Share:

Anika Therapeutics posted 2016 orthobiologic revenue of US $89.7MM, +22.5% vs. 2015, with 4Q16 revenue of $24.4MM, +13.2% vs. 4Q15.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.